Sanovas seeks $25 million as it gears up to go commercial

November 13, 2012 by Brad Perriello

Medical device company Sanovas is looking to raise about $25 million to commercialize its next-generation Vas Zeppelin pulmonary device designed to scan, diagnose and treat lung disease in a single sitting.

Sanovas CEO Larry Gerrans

Most startup medical device companies raise 10s of millions to research and develop their products before they even get to the commercial stage. But for Sanovas and co-founder Larry Gerrans, the 12-year journey to that point required a scant $9 million – all raised from the pulmonary device firm's founders, friends and family, Gerrans told MassDevice.com last month.

"We've built the company with significant fiscal constraint. We've been very engineering-eccentric. I've been everything you can imagine, I've been in intellectual property, I've been operations, been managing the engineers," Gerrans told us. "We've grown strong, we've not grown fast. We've really paid attention to what the physicians have been asking for, getting good strong feedback from them."

The Sanovas Vas Zeppelin device is more like 5 devices in 1, involving imaging, catheter-based access and intervention, "smart" technology and drug delivery – all on a scale small enough to fit into the 1mm to 3mm commonly found in the lungs outer reaches. It's designed to eliminate the need to crack open patients' chests to access the lungs – and the 7-day in-hospital recovery time for such procedures.

Sign up to get our free newsletters delivered straight to your inbox

Earlier this year Sanovas built out its Sausalito, Calif., headquarters to add administration and manufacturing space. Now, in anticipation of 510(k) clearance from the FDA, Sanovas is looking to drum up about $25 million to commercialize the Vas Zeppelin for the U.S. market, Gerrans told us at the AdvaMed 2012 convention in Boston in October. We asked Gerrans to bring us up to date on Sanovas, which we last profiled at AdvaMed 2011 in Washington last year.

MassDevice.com: In the year since we last spoke, Sanovas has focused on developing the engineering behind its technology. Can you bring us up to date on the company?

Comments

Features

David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

MassDevice.com brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at MassDevice.com's DeviceTalks Boston event.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp